Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomics of first-line irinotecan plus cisplatin in small cell lung cancer
ChiCTR-RCH-11001494Phase 4Completed
- Sponsor
- Tongji Medical College
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of irinotecan and cisplatin in small cell lung cancer (SCLC) (2 arms), sponsored by Tongji Medical College. Primary endpoints: Objective response rate, Incidence of grade III or higher diarrhea and 1 more. Started Aug 2011; status: completed.
02
Drugs
irinotecancisplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR-RCH-11001494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-RCH-11001494.